Steve, living with hemophilia in Kenya
People living with hemophilia in Kenya face a number of challenges that people in developed countries may not face, such as access to a quick and accurate diagnosis, sustained availability to clotting factor–to replace missing blood clotting factors–and disease awareness and education.
The World Federation of Hemophilia (WFH) Humanitarian Aid Program has created a sustainable supply of factor therapy in Kenya and other developing nations, helping to improve overall standard of care. The predictable supply of factor therapy allows for prophylactic (preventive) treatment and corrective surgeries and is no longer reserved for emergencies.
Together with Sobi, an international rare disease company, Sanofi Genzyme’s commitment has provided more than 450 million international units (IUs) of clotting factor to the program, which has helped to treat over 17,200 people in over 40 countries. In June 2020, Sanofi Genzyme and Sobi committed up to 500 million additional IUs of clotting factor to the WFH Humanitarian Aid program, delivering on the 2014 pledge to donate up to 1 billion IUs for humanitarian use.
Bonnie Anderson, Head of Humanitarian Programs for Sanofi Genzyme, traveled with the WFH to Kenya where she witnessed first-hand the positive impact the WFH Humanitarian Aid Program has had on the community.
“The WFH has done a wonderful job of bringing people together and creating a community focused on complete patient care. The fact that our company, together with Sobi and the WFH, has helped provide this opportunity to patients and families through our donation is wonderful, and I feel privileged to be part of it,” Bonnie said.
Sanofi Genzyme and Sobi’s donation is making a life-changing impact for patients in the developing world, helping to treat over 160,000 acute bleeds; enabling more than 2,300 surgeries, including life and limb-saving operations; and helping to increase the percentage of children receiving treatment from 14 to 37 percent.